Articles Insights From the Experts at Teiko Learn about the latest advances in immune profiling from Teiko’s team of scientific experts. All Topics Customer Spotlight Educational Webinar Expert Interview Immune Profiling Mass Cytometry Technology Immune responses to cancer immunotherapy outside the tumor Where do T cells get activated after cancer immunotherapy? Matthew Spitzer, PhD, reviews current literature and his lab’s recent Cell publication in this educational webinar. Read Article Matt Spitzer, PhD: Understanding the immune setpoint – a new approach to cancer treatment Matthew Spitzer, Associate Professor at UCSF and scientific cofounder of Teiko Bio, explains how understanding each patient’s individual “immune setpoint” could be the key to maximizing cancer treatment efficacy. Read Article Five things to look for in an immune profiling partner Make the most of your time and resources by choosing an immune profiling partner who can advance your oncology, autoimmune, or infectious disease pipelines. Here are five things to look for when evaluating an immune profiling partner. Read Article What the Costco hot dog teaches us about our immune system What the Costco hotdog and soda deal and inflation can teach us about better understanding the immune system. Read Article Customer Spotlight: Shernan Holtan, MD Dr. Shernan Holtan discusses her research into a pregnancy hormone that may hold the key to treating life-threatening graft-vs-host diseases and how Teiko helped her overcome the barriers to high-dimensional immune profiling. Read Article Two peas in a pod: The complementary capabilities of single-cell RNA seq and mass cytometry Researchers have used scRNAseq and CyTOF as complementary tools in a wide variety of published studies to provide additional breadth, depth, and coverage when analyzing cellular processes. Here are a few specific examples that illustrate the diversity and range of these approaches in a variety of biomedical research settings. Read Article Peripheral blood analysis is key to developing effective cancer immunotherapies Although most research focuses on tumor-killing immune cells at the site of the tumor, new research increasingly demonstrates the value of studying circulating immune cells in peripheral blood to identify new therapeutic targets to enhance tumor-killing immune responses. We highlight recent publications with peripheral blood biomarkers and discuss recommendations for how to incorporate peripheral blood immune profiling into your drug development pipeline. Read Article Flow vs. Spectral vs. Mass Cytometry: What’s the difference? What’s the difference between flow, spectral, and mass cytometry? We highlight the differences between these three different cytometry platforms used by drug developers to characterize the immune system so you can determine which platform provides you the richest information to advance your research and therapeutic development. Read Article
Immune responses to cancer immunotherapy outside the tumor Where do T cells get activated after cancer immunotherapy? Matthew Spitzer, PhD, reviews current literature and his lab’s recent Cell publication in this educational webinar. Read Article
Matt Spitzer, PhD: Understanding the immune setpoint – a new approach to cancer treatment Matthew Spitzer, Associate Professor at UCSF and scientific cofounder of Teiko Bio, explains how understanding each patient’s individual “immune setpoint” could be the key to maximizing cancer treatment efficacy. Read Article
Five things to look for in an immune profiling partner Make the most of your time and resources by choosing an immune profiling partner who can advance your oncology, autoimmune, or infectious disease pipelines. Here are five things to look for when evaluating an immune profiling partner. Read Article
What the Costco hot dog teaches us about our immune system What the Costco hotdog and soda deal and inflation can teach us about better understanding the immune system. Read Article
Customer Spotlight: Shernan Holtan, MD Dr. Shernan Holtan discusses her research into a pregnancy hormone that may hold the key to treating life-threatening graft-vs-host diseases and how Teiko helped her overcome the barriers to high-dimensional immune profiling. Read Article
Two peas in a pod: The complementary capabilities of single-cell RNA seq and mass cytometry Researchers have used scRNAseq and CyTOF as complementary tools in a wide variety of published studies to provide additional breadth, depth, and coverage when analyzing cellular processes. Here are a few specific examples that illustrate the diversity and range of these approaches in a variety of biomedical research settings. Read Article
Peripheral blood analysis is key to developing effective cancer immunotherapies Although most research focuses on tumor-killing immune cells at the site of the tumor, new research increasingly demonstrates the value of studying circulating immune cells in peripheral blood to identify new therapeutic targets to enhance tumor-killing immune responses. We highlight recent publications with peripheral blood biomarkers and discuss recommendations for how to incorporate peripheral blood immune profiling into your drug development pipeline. Read Article
Flow vs. Spectral vs. Mass Cytometry: What’s the difference? What’s the difference between flow, spectral, and mass cytometry? We highlight the differences between these three different cytometry platforms used by drug developers to characterize the immune system so you can determine which platform provides you the richest information to advance your research and therapeutic development. Read Article
